BAY-1816032
BAY-1816032 is a potent orally administered BUB1 (budding not inhibited by benzimidazole 1) kinase inhibitor with an IC50 of 7 nM. In cellular analyses, it has synergistic or additive effects in combination with paclitaxel or docetaxel and ATR or PARP inhibitors. Tumor xenograft studies demonstrated that BAY-1816032, when combined with paclitaxel or olaparib, resulted in significant and statistically significant reductions in tumor size and excellent tolerability compared with their respective monotherapy.
| Supplier | Alfa Cytology |
|---|---|
| Product # | BC0012 |
| Pricing | 50.0 mg, 100.0 mg, 200.0 mg, 500.0 mg, 1.0 g, 2.0 g, inquire |